NAT: Perspectives for cellular components

Biologicals

Volumn 27, Issue 4, 1999, Pages 333-336

  Barbara, John A J ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; VIRUS RNA;

BLOOD COMPONENT; BLOOD DONOR; CONFERENCE PAPER; COST BENEFIT ANALYSIS; FRACTIONATION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; NUCLEIC ACID ANALYSIS; PLASMA; PRIORITY JOURNAL; SEROCONVERSION; SHELF LIFE; THROMBOCYTE; VIRUS GENOME; VIRUS INFECTION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033501397     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0228     Document Type: Conference Paper

References (18)

1. Committee for Proprietary Medicinal Products, Intramuscular immunoglobulins: nucleic acid amplification tests for HCV RNA detection, European Agency for the Evaluation of Medicinal Products, 1995, CPMP/117/95 final.
2. Committee for Proprietary Medicinal Products, Note for guidance on plasma derived medicinal products: the introduction of genomic amplification technology for plasma pool testing, European Agency for the Evaluation of Medicinal Products, 1998, CPMP/BWP/390/97.
3. Bundesanzeiger. 53:1998; 3835-3836.
4. Roth WK, Webster ML, Seifried E. Feasibility and efficacy routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood bank setting. Lancet. 30:1999; 63-359.
5. Schreiber GB, Busch MP, Kleinmann SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Eng J Med. 334:1996; 1685-1690.
6. Pillonel J, Saura C, Courouce AM. Screening of viral markers for HIV, HBV and HCV infections in France and residual risk of viral transmission by blood transfusion. Eurosurveillance. 3:1998; 76-79.
7. Glück D, Kubanek B, Maurer C, Petersen N. Seroconversion of HIV, HCV and HBV in Blood Donors in 1996 - Risk of Virus Transmission by Blood Products in Germany. Infusionther Tranfusionsmed. 25:1998; 82-84.
8. Nübling CM, Seitz R, Löwer J. Application of Nucleic Acid Amplification Techniques for Blood Donation Screening. Infusionther Tranfusionsmed. 25:1998; 86-90.
9. Communicable disease report. HIV infection transmitted through transfusion.
10. Barbara JAJ, Hepatitis B. Overview, new problems. Vox Sang. 61:1994; 239-242.
11. Hewitt PE, Kendall B, Barbara JAJ. Hepatitis A transmitted by red cell transfusion. Transfusion Med. 1:1997; 48.
12. Tan D, Matsumoto A, Contry-Cantilena C. Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. J Infect Dis. 179:1999; 1055-1061.
13. Tacke M, Schmolke S, Schlueter S. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology. 26:1997; 1626-1633.
14. Simmonds P, Davidson F, Lycett C. Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet. 352:1998; 191-195.
15. Müller-Breitkreutz for the EPFA Working Group on Quality Assurance, Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997, Vox Sang.
16. Busch M, Stramer SL. The efficiency of HIV p24 antigen screening of US blood donors: projections versus reality. Infusionsther Transfusionsmed. 25:1998; 194-197.
17. The Serious Hazards of Transfusion Committee, SHOT annual report.
18. The Serious Hazards of Transfusion Committee, SHOT annual report.